Overview

Efficacy and Safety of a Reduced Immunosuppression vs. Standard Triple Therapy in Senior Renal Transplant Recipients

Status:
Unknown status

Trial end date:
2019-07-01

Target enrollment:

Participant gender:

Summary

Study purpose To establish efficacy and safety of a reduced immunosuppressive therapy with tacrolimus once daily for senior (>65 years of age) renal transplant recipients

Phase:

Phase 4

Details

Lead Sponsor:

Klemens Budde

Collaborators:

Charite University, Berlin, Germany
DESCARTES Working Group On Transplantation
EKITA (European Kidney Transplant Association)
ERA-EDTA (Europ. Renal Association-Europ. Dialysis and Transplant Association)
European Kidney Transplant Association (EKITA)
European Renal Association - European Dialysis and Transplant Association
Koordinierungszentrum Klinischer Studien (KKS) Charité Berlin, Germany

Treatments:

Mycophenolate mofetil
Mycophenolic Acid
Tacrolimus